SLC5A2 and chronic kidney disease: Importantly, these findings were achieved despite heterogeneity in trial populations, including patients with established ASCVD, CKD, and multiple cardiovascular risk factors, underscoring the broad applicability of SGLT2 inhibitors across diverse high-risk subgroups.